Solstein Capital’s AbbVie ABBV Stock Holding History

Solstein Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$241K	Sell	1,110 -350	-24%	-$77.6K	0.1%	122
2025 Q4	$334K	Hold	1,460	–	–	0.13%	101
2025 Q3	$338K	Hold	1,460	–	–	0.08%	97
2025 Q2	$271K	Buy	1,460 +350	+32%	+$65K	0.14%	98
2025 Q1	$233K	Hold	1,110	–	–	0.14%	86
2024 Q4	$197K	Hold	1,110	–	–	0.11%	97
2024 Q3	$219K	Hold	1,110	–	–	0.12%	97
2024 Q2	$190K	Hold	1,110	–	–	0.12%	94
2024 Q1	$202K	Sell	1,110 -235	-17%	-$40.5K	0.14%	90
2023 Q4	$208K	Hold	1,345	–	–	0.15%	87
2023 Q3	$200K	Hold	1,345	–	–	0.17%	84
2023 Q2	$181K	Hold	1,345	–	–	0.15%	86
2023 Q1	$214K	Hold	1,345	–	–	0.19%	84
2022 Q4	$217K	Hold	1,345	–	–	0.18%	87
2022 Q3	$181K	Sell	1,345 -90	-6%	-$12.9K	0.16%	87
2022 Q2	$220K	Hold	1,435	–	–	0.17%	93
2022 Q1	$233K	Hold	1,435	–	–	0.15%	103
2021 Q4	$194K	Hold	1,435	–	–	0.12%	128
2021 Q3	$155K	Hold	1,435	–	–	0.09%	149
2021 Q2	$162K	Buy	1,435 +374	+35%	+$42.1K	0.2%	119
2021 Q1	$115K	Buy	+1,061	New	+$113K	0.16%	145
2020 Q4	–	Sell	-935	Closed	-$82K	–	85
2020 Q3	$82K	Hold	935	–	–	0.18%	99
2020 Q2	$92K	Buy	935 +112	+14%	+$9.86K	0.22%	82
2020 Q1	$63K	Buy	823 +466	+131%	+$39.7K	0.24%	67
2019 Q4	$32K	Buy	+357	New	+$29.6K	0.06%	142

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Solstein Capital's ABBV Position: Q1 2026 in Review

Solstein Capital reduced its AbbVie (ABBV) stake by 24% in Q1 2026, selling an estimated $77.6K and leaving 1,110 shares worth $241K. The position accounts for 0.1% of the portfolio, ranked #122.

Solstein Capital first reported a position in ABBV in Q4 2019 and has held it in 25 quarters since. The position peaked at $338K in Q3 2025. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Solstein Capital held 1,110 shares of AbbVie worth $241K as of Q1 2026.
Solstein Capital sold 350 AbbVie shares in Q1 2026, an estimated $77.6K.
AbbVie made up 0.1% of Solstein Capital's portfolio in Q1 2026, its #122 holding.
Solstein Capital first reported a position in AbbVie in Q4 2019 and has held it in 25 quarters since.
Solstein Capital's AbbVie position peaked at $338K in Q3 2025.
4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Solstein Capital's 13F filing for Q1 2026, filed 14 May 2026.